Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI301 vs Rituximab with CHOP in Untreated DLBCL
NCT02867566Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Aug 2016
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of IBI301 in diffuse large B-cell lymphoma (DLBCL), sponsored by Innovent Biologics. Started Aug 2016; status: completed.
02
Drugs
IBI301
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02867566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867566.